-transparent.png){kind=logo}
Bone marrow aplasia remains the most serious adverse effect with gold therapy. Its prevalence is still a controversial issue and at present it is not possible to give accurate figures on its frequency. Two patients diagnosed of rheumatoid arthritis are reported. They underwent chrysotherapy and developed bone marrow aplasia within a 2-month period of therapy. The pathogenic mechanism of blood dyscrasias secondary to gold salts is still unknown. The best available method in the prevention of this serious condition is the periodical obtention of complete blood counts.
Related Publications
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 1987,
Medicina clinica,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 1985,
Sangre,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 1965,
Journal de medecine de Bordeaux et du Sud-Ouest,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
November 1969,
Ugeskrift for laeger,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 2008,
Acta haematologica,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
June 1977,
Arthritis and rheumatism,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 1991,
Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
June 2014,
Drugs in R&D,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
May 1964,
Toulouse medical,
M C Pérez, and
M T Gómez Casares, and
R Mataix, and
C Campo, and
S Jiménez, and
J J Malcorra
January 1992,
Acta clinica Belgica,
